Tamsulosin

證據等級: L5

預測適應症: 10 個

Tamsulosin: From Lower Urinary Tract Symptoms (BPH) to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Tamsulosin is a selective α1A-adrenergic receptor antagonist, pharmacologically associated with benign prostatic hyperplasia (BPH)/lower urinary tract symptom management, though no formal original-indication or SAHPRA licensing record is present in the available data. The TxGNN model predicts a possible link to Ambras type hypertrichosis universalis congenita, an extremely rare congenital hair-overgrowth disorder, but no clinical trials and no published literature currently support this specific prediction — the evidence pack itself flags it as lacking any known biological hypothesis.

Quick Overview

Item	Content
Original Indication	Not documented in SAHPRA licensing data (drug not currently marketed in South Africa); mechanistically linked to BPH/lower urinary tract symptoms based on the drug’s α1A-adrenergic antagonist class
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	99.996%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not officially available in this evidence pack. Based on the pharmacological class referenced in the model’s rationale, tamsulosin is a selective α1A-adrenergic receptor antagonist that acts primarily on smooth muscle in the prostate and bladder neck — a mechanism with no established connection to hair follicle biology, androgen-mediated hair growth signalling, or WNT/Hedgehog pathway regulation.

Ambras type hypertrichosis universalis congenita is an extremely rare congenital disorder of generalized excessive hair growth. There is no known pharmacological or clinical rationale linking α1A-receptor blockade to this condition’s pathophysiology. The evidence pack’s own repurposing rationale states this explicitly: the prediction is not supported by any biological hypothesis, and the high TxGNN score is more likely explained by proximity clustering of hair-related disease nodes within the knowledge graph embedding space (the same pattern recurs across several other top-ranked predictions for this drug, including “hypertrichosis (disease),” “hypotrichosis simplex of the scalp,” and “congenital hypotrichosis milia”) rather than a genuine pharmacological signal.

Given the complete absence of supporting clinical trials or literature, and the model’s own acknowledgment of no mechanistic plausibility, this prediction should be treated as a low-confidence knowledge-graph artifact rather than a credible repurposing candidate at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Tamsulosin is not currently registered with SAHPRA under this evidence pack (0 licenses on file; market status: Not Marketed). No product registration details are available to report.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has evidence level L5 (model prediction only) — no clinical trials, no literature, and no established mechanistic plausibility. The drug is also not currently marketed in South Africa, and no SAHPRA licensing or safety data are available to support even a preliminary risk assessment.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI), including key warnings and contraindications
Confirmed mechanism of action data (DrugBank or equivalent primary source)
A documented original indication with regulatory basis (current data pack has none)
Any preclinical or mechanistic literature specifically linking α1A-adrenergic antagonism to hair follicle biology, before this candidate can reasonably advance beyond S0
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.